{"schema_version":"secwatch.filing_event.v1","accession":"0001552781-23-000269","form_type":"8-K","ticker":"SWKHL","cik":"0001089907","company_name":"SWK Holdings Corp","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.906678+00:00","generated_at":"2026-06-15T03:31:09.849565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SWK Holdings Q1 net income rises 33% to $4.6M; revenue falls 15% to $9.4M","bullets":["GAAP net income $4.6M ($0.36 diluted EPS) vs $3.5M ($0.27) YoY; revenue $9.4M down 15.3%.","Finance receivables segment adjusted non-GAAP net income $7.3M vs $8.4M YoY; gross receivables $248.8M (+32.2%).","Adopted CECL: $11.8M allowance for credit losses, $9.7M net reduction to accumulated deficit.","Enteris operating expenses down 45% QoQ to $1.4M; bid on $7M CDMO projects for 2H23 growth.","Repurchased 28,766 shares in Q1 for $0.5M; book value per share $21.39."],"urls":{"canonical":"https://secwatch.observer/filing/0001552781-23-000269","json":"https://secwatch.observer/filing/0001552781-23-000269.json","markdown":"https://secwatch.observer/filing/0001552781-23-000269.md","text":"https://secwatch.observer/filing/0001552781-23-000269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1089907/000155278123000269/0001552781-23-000269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1089907/000155278123000269/e231261_swkh-8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:31:09.849565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6646d8536a9f8a70493d6800174984ce7ccca9f1","claim":"SWK Holdings Corp reported first quarter ended March 31, 2023 results: revenue $9.4 million, net income $4.6 million, EPS $0.36 per diluted share.","evidence_excerpt":"For the first quarter 2023, SWK reported total revenue of $9.4 million, a 15.3% decrease compared to $11.1 million for the first quarter 2022. The $1.7 million decrease in revenue for the three months ended March 31, 2023, consisted of a $1.1 million decrease in Finance Receivables segment revenue and a $0.6 million decrease in Pharmaceutical Development segment revenue. The $1.1 million decrease in Finance Receivables segment revenue was primarily due to a $5.3 million decrease in interest, fees and royalties earned on finance receivables that were paid off in 2022, which was partially offset by a $4.4 million increase in interest and fees earned due to funding new and existing loans. Pre-tax net income for the quarter was flat at $4.5 million for the three months ended March 31, 2023, compared to $4.6 million for the same period of the previous year. The slight year-over-year decrease is primarily due to a $1.7 million decrease in consolidated revenue, partially offset by a $1.9 mill","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1089907/000155278123000269/0001552781-23-000269-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$9.4 million"},{"label":"Net income","value":"$4.6 million"},{"label":"EPS","value":"$0.36 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}